查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047034

Q Heat市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、藥物類型、最終用戶、地區和競爭格局分類，2021-2031年

Q Fever Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Medication Type, By End-Users, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 Q 熱市場預計將從 2025 年的 4.4131 億美元成長到 2031 年的 5.9853 億美元，複合年成長率為 5.21%。

該市場涵蓋了用於控制巴氏柯克斯體感染疾病的診斷檢測套組、抗生素治療藥物和預防性疫苗的研發和分銷。這一成長主要得益於政府對牲畜篩檢的嚴格要求以及「同一健康」策略的強化，該策略強調對通用感染疾病的監測。此外，肉類加工和獸醫等高風險行業更嚴格的職業安全法規迫使雇主實施常規預防措施和檢測方案，從而確保了對分子和血清學診斷工具的穩定需求。

市場概覽
預測期 2027-2031
市場規模：2025年 4.4131億美元
市場規模：2031年 5.9853億美元
複合年成長率：2026-2031年 5.21%
成長最快的細分市場 急性Q熱
最大的市場 北美洲

然而，由於疾病的症狀通常模糊不清，且與流感症狀相似，誤診和延誤治療的情況十分普遍，導致漏診成為臨床實踐的一大挑戰。這種診斷上的不確定性導致對實際疾病負擔的低估，並限制了可治療的患者群體。根據歐洲食品安全局（EFSA）的數據，截至2024年，2023年歐盟共報告了805例確診的Q熱病例，比前一年增加了11.5%。這些數據凸顯了疾病的盛行率與檢出率之間持續存在的差距，阻礙了市場擴張。

市場促進因素

全球Q熱感染病例的增加，作為一種通用感染疾病，正在從根本上改變市場環境，因此亟需加強監測系統並引入快速診斷方法。由於病原體伯氏考克斯體（Coxiella burnetii）在環境載體中具有很高的存活率，公共衛生機構正在加強監測活動，以防止集體爆發，從而避免對畜牧業經濟和人類健康造成負面影響。確診病例的增加反映了地方性流行區域的擴大以及農業部門檢測能力的提高。例如，根據Q-GAPS聯盟2025年7月發布的報告《斯洛伐克Q熱集體爆發》，在經歷了數十年的潛伏期後，普里耶維察地區出現了一次顯著的疫情反彈，包括11例住院病例。此外，澳洲衛生和老年護理部在其2025年10月發布的《國家法定傳染病監測系統報告》中指出，2024年10月至2025年10月期間共記錄了951例Q熱病例，這一數字顯著超過了五年移動平均值。

同時，由於現有預防措施的局限性，例如需要進行繁瑣的預篩檢以避免過敏反應，對下一代疫苗研發的投資正在增加。市場正轉向合成疫苗和次單位疫苗技術，這些技術旨在提供免疫力且不引起嚴重的反應原性，從而擴大了針對牲畜和人類的大規模免疫計劃的可能性。政府機構和相關人員正在加強對這些工作的支持力度，以保護農業供應鏈免受牲畜繁殖障礙造成的經濟損失。近期的資金投入凸顯了這個趨勢。根據 Sheep Central 2025 年 2 月發表的一篇報導《Q 熱疫苗需要撥款和研究經費》，新南威爾斯州衛生部向澳洲立克次體參考研究所撥款 20 萬澳元，以加速開發一種新的人類 Q 熱疫苗。此類資金對於將候選疫苗推進臨床試驗以及克服迄今為止限制市場規模的可擴展性障礙至關重要。

市場挑戰

Q熱缺乏臨床診斷是市場成長的主要障礙，因為它掩蓋了疾病的真實流行程度。由於伯氏考克斯體感染疾病通常表現為疲勞和發燒等特異性症狀，醫護人員常將其誤診為常見的病毒性疾病。這種診斷上的模糊性導致必要的診斷檢測未能進行，使得大量患者無法確診。因此，診斷和製藥行業面臨商機，因為對篩檢檢測和抗生素治療的需求直接取決於準確的臨床診斷。

實際發病率與報告病例數之間持續存在的差距限制了目標市場，並阻礙了對先進療法的投資。當病例未被記錄時，新療法的預期投資回報就會降低。澳洲衛生與老年護理部的數據凸顯了這個問題，數據顯示，截至2025年10月的一年中，國家傳染病監測系統僅報告了951例Q熱病例。這些數據表明，儘管監測系統運作良好，但症狀與檢測方案之間的差異仍然限制著全球Q熱市場的擴張。

市場趨勢

向基於PCR的分子診斷的轉變正在從根本上改變全球Q熱市場，以高靈敏度的基因組分析取代傳統的血清學方法。這項技術變革的驅動力在於早期檢測感染和準確量化細菌量的需求，因為基於抗體的檢測方法在急性期往往無法識別這些因素。先進平台的出現正在加速這一轉變，使檢查室能夠以前所未有的精度檢測伯氏考克斯體，即使在複雜的檢體基質中也能做到。為了支持這項進展，凱傑公司（Qiagen NV）在2024年6月發布的新聞稿《凱傑推出用於微生物應用的新型QIAcuity數位PCR檢測》中宣布，該公司已推出35種經濕實驗室測試的新型微生物DNA檢測方法，從而擴展了適用於感染疾病調查和監測的高精度分子診斷工具的可用性。

同時，常規散裝牛奶監測的標準化正成為獸醫學領域的關鍵趨勢，為畜群層面的疾病管理提供了可擴展的解決方案。這種方法從個別篩檢轉向混合牛奶的總結採樣，從而能夠經濟高效地識別乳牛攜帶病原體的排放率。事實證明，該方法在揭示地方性疾病流行的農業地區的潛在疾病負擔方面非常有效。例如，根據Ceva Animal Health於2024年10月發布的《2024年秋季Q熱新聞更新》，對自2020年以來收集的900份散裝牛奶樣本的分析顯示，累積陽性率為46%，這表明該散裝篩檢方案在維護農業生物安全方面得到了廣泛應用，並具有診斷效用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球Q熱市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（急性Q熱、慢性Q熱）
    • 依藥物類型（抗生素、抗瘧疾藥、皮質類固醇、其他）
    • 依最終用戶（醫院、診所、研究機構）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美Q熱市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲Q熱市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區熱能市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：Q Heat在中東和非洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲Q熱市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球Q熱市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Sun Pharmaceutical Industries Ltd.
  • Abbott Laboratories Inc.
  • Aurobindo Pharma Limited
  • Pfizer Inc.
  • Lupin Limited
  • Bayer AG
  • Novartis Pharmaceuticals Corporation
  • GSK plc
  • Merck & Co., Inc.
  • Sanofi SA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20242

The Global Q Fever Market is projected to increase from USD 441.31 Million in 2025 to USD 598.53 Million by 2031, expanding at a CAGR of 5.21%. This market covers the creation and distribution of diagnostic assays, antibiotic treatments, and preventive vaccines designed to manage infections caused by the bacterium Coxiella burnetii. Growth is largely fueled by strict government requirements for livestock screening and the reinforcement of "One Health" strategies that emphasize the surveillance of zoonotic diseases. Furthermore, elevated occupational safety regulations in high-risk industries, such as meat processing and veterinary medicine, are forcing employers to implement routine prophylaxis and testing protocols, ensuring a consistent demand for molecular and serological diagnostic tools.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 441.31 Million
Market Size 2031USD 598.53 Million
CAGR 2026-20315.21%
Fastest Growing SegmentAcute Q Fever
Largest MarketNorth America

However, the market faces a major hurdle due to the clinical underdiagnosis of the condition, as its vague symptoms often resemble influenza, resulting in misidentification and delayed medical treatment. This diagnostic uncertainty hides the true disease burden and restricts the potential patient population for therapeutics. According to the "European Food Safety Authority," in "2024," there were 805 confirmed human cases of Q fever reported in the European Union for 2023, marking an 11.5% rise from the prior year. This data underscores the ongoing gap between disease prevalence and detection that hinders market scalability.

Market Driver

The rising global prevalence of zoonotic Q fever infections is fundamentally altering the market landscape by necessitating stronger surveillance frameworks and rapid diagnostic deployment. Because the pathogen Coxiella burnetii shows resilience in environmental reservoirs, public health agencies are increasing monitoring efforts to prevent outbreaks that harm livestock economies and human health. This increase in identified cases reflects both expanding endemic zones and improved detection capabilities within agricultural sectors. For example, according to the Q-GAPS Consortium in July 2025, the "Q fever outbreak in Slovakia" report confirmed a significant resurgence with 11 human hospitalizations in the Prievidza district after decades of dormancy. Additionally, the Australian Government Department of Health and Aged Care reported in October 2025, in the "National Notifiable Diseases Surveillance System" report, that 951 Q fever notifications were recorded between October 2024 and October 2025, a figure significantly higher than the five-year rolling average.

A parallel driver is the growing investment in next-generation vaccine research and development, motivated by the limitations of current prophylaxis which often requires difficult pre-screening to avoid hypersensitivity. The market is shifting toward synthetic and subunit vaccine technologies designed to provide immunity without severe reactogenicity, thereby expanding the potential for mass immunization programs for livestock and humans. Government entities and financial stakeholders are increasingly supporting these initiatives to protect agricultural supply chains from economic losses linked to reproductive failures in herds. This trend is highlighted by recent funding; according to Sheep Central in February 2025, in the article "Q Fever vaccine subsidy and research funding needed," the New South Wales Health Department granted AUD 200,000 to the Australian Rickettsial Reference Laboratory to speed up the development of a new human Q fever vaccine. Such funding is crucial for moving candidates through clinical trials and overcoming the scalability barriers that have historically limited the market.

Market Challenge

The clinical underdiagnosis of Q fever represents a primary obstacle to market growth by masking the true prevalence of the disease. Since Coxiella burnetii infection frequently presents with non-specific symptoms like fatigue and fever, healthcare providers often mistake the condition for common viral illnesses. This ambiguity results in a failure to order the necessary diagnostic tests, leaving a large portion of the patient population undiagnosed. Consequently, the diagnostic and pharmaceutical sectors face reduced revenue potential because the demand for screening assays and antibiotic therapies is directly dependent on accurate clinical identification.

This continuing gap between actual incidence and reported figures limits the addressable market and discourages investment in advanced countermeasures. When cases go unrecorded, the perceived return on investment for new therapeutics decreases. Highlighting this issue, according to the "Australian Department of Health and Aged Care," in "2025," there were 951 notified cases of Q fever reported to the National Notifiable Diseases Surveillance System for the year ending in October. This data indicates that while surveillance is active, the disconnect between symptoms and testing protocols continues to restrict the scalable expansion of the Global Q Fever Market.

Market Trends

The transition to PCR-based molecular diagnostics is fundamentally transforming the Global Q Fever Market by replacing traditional serological methods with high-sensitivity genomic analysis. This technological shift is driven by the necessity for early-stage infection detection and precise quantification of bacterial loads, which antibody-based tests often fail to identify during the acute phase. The availability of advanced platforms is accelerating this transition, enabling laboratories to detect Coxiella burnetii with unprecedented accuracy across complex sample matrices. Underscoring this advancement, according to Qiagen N.V. in June 2024, in the press release "QIAGEN launches new QIAcuity digital PCR assays for microbial applications," the company introduced 35 new wet-lab tested microbial DNA detection assays, thereby expanding the accessibility of high-precision molecular testing tools suitable for infectious disease research and surveillance.

Simultaneously, the standardization of routine bulk tank milk monitoring is emerging as a critical trend in the veterinary sector, providing a scalable solution for herd-level disease management. This approach moves away from individual animal screening towards aggregate sampling of commingled milk, enabling cost-effective identification of shedding prevalence in dairy livestock reservoirs. This method has proven highly effective in revealing the cryptic burden of the disease in endemic agricultural regions. For instance, according to Ceva Animal Health in October 2024, in the "Q Fever News Update Autumn 2024," an analysis of 900 bulk tank milk samples collected since 2020 revealed a cumulative positivity rate of 46%, demonstrating the widespread adoption and diagnostic utility of this bulk screening protocol for maintaining agricultural biosecurity.

Key Market Players

  • Sun Pharmaceutical Industries Ltd.
  • Abbott Laboratories Inc.
  • Aurobindo Pharma Limited
  • Pfizer Inc.
  • Lupin Limited
  • Bayer AG
  • Novartis Pharmaceuticals Corporation
  • GSK plc
  • Merck & Co., Inc.
  • Sanofi SA

Report Scope

In this report, the Global Q Fever Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Q Fever Market, By Type

  • Acute Q Fever
  • Chronic Q Fever

Q Fever Market, By Medication Type

  • Antibiotics
  • Antimalerial
  • Corticosteroids
  • Others

Q Fever Market, By End-Users

  • Hospitals
  • Clinics
  • Research Institutes

Q Fever Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Q Fever Market.

Available Customizations:

Global Q Fever Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Q Fever Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Acute Q Fever, Chronic Q Fever)
    • 5.2.2. By Medication Type (Antibiotics, Antimalerial, Corticosteroids, Others)
    • 5.2.3. By End-Users (Hospitals, Clinics, Research Institutes)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Q Fever Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Medication Type
    • 6.2.3. By End-Users
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Q Fever Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Medication Type
        • 6.3.1.2.3. By End-Users
    • 6.3.2. Canada Q Fever Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Medication Type
        • 6.3.2.2.3. By End-Users
    • 6.3.3. Mexico Q Fever Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Medication Type
        • 6.3.3.2.3. By End-Users

7. Europe Q Fever Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Medication Type
    • 7.2.3. By End-Users
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Q Fever Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Medication Type
        • 7.3.1.2.3. By End-Users
    • 7.3.2. France Q Fever Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Medication Type
        • 7.3.2.2.3. By End-Users
    • 7.3.3. United Kingdom Q Fever Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Medication Type
        • 7.3.3.2.3. By End-Users
    • 7.3.4. Italy Q Fever Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Medication Type
        • 7.3.4.2.3. By End-Users
    • 7.3.5. Spain Q Fever Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Medication Type
        • 7.3.5.2.3. By End-Users

8. Asia Pacific Q Fever Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Medication Type
    • 8.2.3. By End-Users
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Q Fever Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Medication Type
        • 8.3.1.2.3. By End-Users
    • 8.3.2. India Q Fever Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Medication Type
        • 8.3.2.2.3. By End-Users
    • 8.3.3. Japan Q Fever Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Medication Type
        • 8.3.3.2.3. By End-Users
    • 8.3.4. South Korea Q Fever Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Medication Type
        • 8.3.4.2.3. By End-Users
    • 8.3.5. Australia Q Fever Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Medication Type
        • 8.3.5.2.3. By End-Users

9. Middle East & Africa Q Fever Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Medication Type
    • 9.2.3. By End-Users
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Q Fever Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Medication Type
        • 9.3.1.2.3. By End-Users
    • 9.3.2. UAE Q Fever Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Medication Type
        • 9.3.2.2.3. By End-Users
    • 9.3.3. South Africa Q Fever Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Medication Type
        • 9.3.3.2.3. By End-Users

10. South America Q Fever Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Medication Type
    • 10.2.3. By End-Users
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Q Fever Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Medication Type
        • 10.3.1.2.3. By End-Users
    • 10.3.2. Colombia Q Fever Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Medication Type
        • 10.3.2.2.3. By End-Users
    • 10.3.3. Argentina Q Fever Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Medication Type
        • 10.3.3.2.3. By End-Users

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Q Fever Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sun Pharmaceutical Industries Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories Inc.
  • 15.3. Aurobindo Pharma Limited
  • 15.4. Pfizer Inc.
  • 15.5. Lupin Limited
  • 15.6. Bayer AG
  • 15.7. Novartis Pharmaceuticals Corporation
  • 15.8. GSK plc
  • 15.9. Merck & Co., Inc.
  • 15.10. Sanofi SA

16. Strategic Recommendations

17. About Us & Disclaimer